Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
personal-finance
Can you achieve global diversification with multinational companies?
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,021.90 | 60.20 | 0.76% |
CAC 40 | 7,285.86 | 44.11 | -0.60% |
DAX 40 | 21,205.86 | 105.16 | -0.49% |
Dow JONES (US) | 38,170.41 | 971.82 | -2.48% |
FTSE 100 | 8,275.66 | 0.06 | 0.00% |
HKSE | 21,395.14 | 338.16 | 1.61% |
NASDAQ | 15,870.90 | 415.55 | -2.55% |
Nikkei 225 | 34,279.92 | 450.36 | -1.30% |
NZX 50 Index | 12,082.26 | 36.73 | -0.30% |
S&P 500 | 5,158.20 | 124.50 | -2.36% |
S&P/ASX 200 | 7,819.10 | 60.20 | 0.78% |
SSE Composite Index | 3,280.34 | 4.34 | 0.13% |